NEW YORK (GenomeWeb) – CRISPR Therapeutics late on Friday filed for an initial public offering on the Nasdaq.

In a filing with the US Securities and Exchange Commission, the company said it intends to sell up to $90 million of its common stock. The timing of the offering, as well as the number and price of shares to be sold, were not disclosed. Citigroup, Piper Jaffray, Barclays, and Guggenheim Securities are underwriting the transaction.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

The London School of Economics' Daniele Fanelli argues at the Proceedings of the National Academy of Sciences that the reproducibility crisis in science isn't as dire as some say.

A team of researchers in Portugal has examined the genomic basis for racing pigeons' athleticism and navigational skills, finding it's likely polygenic.

Wired reports that diagnostic firms continue to seek, post-Theranos, the ability to diagnose diseases from small amounts of blood.

In Science this week: analysis of DNA from ancient North Africans, and more.